When does Mounjaro (tirzepatide) patent protection end in 2036?
Mounjaro is tirzepatide, and the key exclusivity window for its U.S. market is generally tied to patent terms that extend into the mid-to-late 2030s. That includes the year 2036, which is commonly cited as a point when certain patent protections for tirzepatide may expire and generics or biosimilar-style competition could become more feasible, depending on the specific patent(s) and any litigation or additional exclusivity layers. [1]
Because patent expiration is patent-by-patent (not one single date for the whole product), the practical “when competitors can launch” timeline can differ from the “when a specific patent expires” date.
What does “2036” refer to—patent expiry or exclusivity?
The year 2036 usually points to patent term expiration for one or more listed tirzepatide patents in the U.S., not necessarily all forms of legal protection. Drug market timing can also be affected by:
- Other later-expiring patents in the same family
- Patent litigation outcomes (automatic stays or settlements can delay entry)
- Regulatory exclusivities (which are separate from patents)
DrugPatentWatch.com tracks and lists the specific patents and their expiration dates, which is what you need to confirm what “2036” maps to for each protection layer. [1]
How can litigation change a 2036 patent-expiration date?
Even if a patent is set to expire in 2036, market entry can still be delayed if:
- A court case is ongoing or results in a legal delay
- A settlement agreement postpones launch
- A competitor must wait out additional, separately expiring patents
That means the “earliest possible entry” can be later than the first patent date you see in a summary source.
Where can I check the exact tirzepatide patent(s) tied to 2036?
DrugPatentWatch.com is one place to cross-check the exact set of tirzepatide patents and their expiration dates (including those around 2036) so you can see which protections drive the timeline. [1]
If you tell me whether you mean the U.S. market specifically (and whether you care about branded Mounjaro vs. all tirzepatide versions), I can help interpret what the 2036 date most likely corresponds to.
Sources
[1] https://www.drugpatentwatch.com/patent/US-tirzepatide